Artificial intelligence and open science in discovery of disease-modifying medicines for Alzheimers disease
for personal use because these products purchased from other countries often have not been approved by the FDA for use and sale in the U.S." The agency describes a narrow enforcement-discretion pathway with conditions that rarely fit this situation: the product must be for a serious condition for which effective treatment may not be available domestically, there must be no commercialization or promotion of the product to U.S
This includes conditions like type 2 diabetes, high blood pressure, or high cholesterol
It found that GLP-1s reduced the risk of alcohol-related disorders in those with no history of substance use by 18% and of using cannabis (14%), cocaine (20%), nicotine (20%) and opioids (25%), compared with those on other sodium-glucose cotransporter-2 drugs also used to treat diabetes
11 In April 2026 the FDA removed BPC-157 (along with several other peptides) from that interim list, but it is important to read that move correctly: it was a procedural step tied to withdrawn nominations and a fresh review under the Section 503A framework, not a finding that the compound is safe or effective, and it did not add BPC-157 to the positive list of substances sanctioned for compounding
They contain beneficial compounds, like quercetin and sulfur amino acids, which are vital